M Bouvet

Summary

Affiliation: University of California
Country: USA

Publications

  1. Miyake K, Murata T, Murakami T, Zhao M, Kiyuna T, Kawaguchi K, et al. Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model. Arch Gynecol Obstet. 2019;: pubmed publisher
    ..001 and P = 0.026, respectively). Salmonella typhimurium A1-R has potential future clinical application to overcome drug resistance in cervical cancer. ..
  2. Kawaguchi K, Igarashi K, Miyake K, Lwin T, Miyake M, Kiyuna T, et al. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Tissue Cell. 2018;52:124-128 pubmed publisher
    ..However, GEM?+?TRA inhibited the PDOX tumor growth significantly greater than TRA alone. These results suggest the clinical potential of the combination of TRA and GEM for pancreatic cancer. ..
  3. Hiroshima Y, Maawy A, Sato S, Murakami T, Uehara F, Miwa S, et al. Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice. J Surg Res. 2014;187:510-7 pubmed publisher
    ..The results described in the present report suggest that the hand-held mobile imaging system can be applied to the clinic for FGS because of its convenient size and high sensitivity which should help make FGS widely used. ..
  4. Bouvet M, Hoffman R. Tumor imaging technologies in mouse models. Methods Mol Biol. 2015;1267:321-48 pubmed publisher
    ..These fluorescent models are powerful and reliable tools with which to investigate metastatic human cancer and novel therapeutic strategies directed against it. ..
  5. Hiroshima Y, Maawy A, Zhang Y, Murakami T, Momiyama M, Mori R, et al. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC). Pancreatology. 2015;15:295-301 pubmed publisher
    ..007, respectively). NAC did not significantly reduce recurrence rates when combined with either FGS or BLS. These results indicate that FGS can significantly reduce local recurrence compared to BLS in pancreatic cancer resistant to NAC. ..
  6. Hiroshima Y, Maawy A, Zhang Y, Guzman M, Heim R, Makings L, et al. Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Ann Surg Oncol. 2015;22 Suppl 3:S1469-74 pubmed publisher
    ..9 mg for BLS + PIT-treated mice (p = 0.015). Anti-CEA-IR700 was able to label and illuminate a pancreatic cancer PDOX nude mouse model sufficiently for PIT. PIT reduced recurrence by eliminating remaining residual cancer cells after BLS. ..
  7. Weiss A, Parina R, Tang J, Brumund K, Chang D, Bouvet M. Outcomes of thyroidectomy from a large California state database. Am J Surg. 2015;210:1170-6; discussion 1176-7 pubmed publisher
    ..6 to .97; P = .026). Older age was a significant risk factor for complication after thyroidectomy. High-volume hospitals had lower risk. This information is useful in counseling patients about the risks of thyroid surgery. ..
  8. Maawy A, Hiroshima Y, Zhang Y, Garcia Guzman M, Luiken G, Kobayashi H, et al. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models. J Surg Res. 2015;197:5-11 pubmed publisher
    ..Further studies are warranted to investigate the potential toxicities of PIT, especially with regard to anastomoses, such as those involved in pancreaticoduodenectomy. ..
  9. Metildi C, Kaushal S, Luiken G, Hoffman R, Bouvet M. Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model. J Am Coll Surg. 2014;219:132-41 pubmed publisher
    ..635-2.365) to 7 weeks with FGLS (95% CI, 5.955-8.045; p = 0.001). Fluorescence-guided laparoscopic surgery is more effective than BLLS and, therefore, has important potential for surgical oncology. ..

More Information

Publications13

  1. Lwin T, Murakami T, Miyake K, Yazaki P, Shivley J, Hoffman R, et al. Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Ann Surg Oncol. 2018;25:1079-1085 pubmed publisher
    ..6) at 48 h. hM5A-IR800 demonstrated excellent tumor localization and a very bright signal. It is a promising agent for future clinical fluorescence-guided surgery applications. ..
  2. request reprint
    Hwang H, Kang C, Lee S, Murakami T, Kiyuna T, Kim S, et al. Fluorescence-guided Surgery with Splenic Preservation Prevents Tumor Recurrence in an Orthotopic Nude-mouse Model of Human Pancreatic Cancer. Anticancer Res. 2018;38:665-670 pubmed
    ..25%, p=0.467). Postoperative tumor recurrence only occurred in the splenectomy-treated group suggesting that FGS can spare the patient the morbidity of splenectomy. ..
  3. DeLong J, Murakami T, Yazaki P, Hoffman R, Bouvet M. Near-infrared-conjugated humanized anti-carcinoembryonic antigen antibody targets colon cancer in an orthotopic nude-mouse model. J Surg Res. 2017;218:139-143 pubmed publisher
    ..Given the ability of this technology to target and label tumors with great specificity, the anti-CEA-IRDye800CW is currently being developed for clinical use in fluorescence-guided surgery. ..
  4. DeLong J, Ward E, Lwin T, Brumund K, Kelly K, Horgan S, et al. Indocyanine green fluorescence-guided parathyroidectomy for primary hyperparathyroidism. Surgery. 2018;163:388-392 pubmed publisher
    ..The operations were performed safely with minimal blood loss and short operative times. Indocyanine green angiography has the potential to assist surgeons in identifying parathyroid glands rapidly with minimal risk. ..